The recent positive speculation about the removal of trade tariffs from China this quarter was squashed by a massive cap raise of $825m at 10.80 per share to fund the acquisition of high-end Californian wine group Daou Vineyards in a deal worth up to $US1 billion ($1.6 billion) as it steps up expansion in the United States luxury wine market.
Incitec Pivot Limited (IPL) is a manufacturer and distributor of industrial explosives, industrial chemicals and fertilisers to the agriculture and mining industries.
Stanmore Resources (SMR) owns and operates the Isaac Plains Complex in Queensland’s prime Bowen Basin region which includes the Isaac Plains Mine and processing facilities, the adjoining Isaac Plains East (operational), Isaac Downs Project (under development) and the Isaac Plains Underground Project.
With the recent run in RMD we are looking to bank some profits here at $29 (+20%) while we see further upside in the stock, the risk that further developments in the GLP-1 space could derail this recent run. Particularly a study due from Eli Lily a maker of Zepbound in the next month.
We still prefer exposure in the healthcare space and are recommending a switch of our RMD allocation to Clinuvel (CUV) a skin disease treatment for sufferers of EPP. They are also in Phase 2 of a stroke treatment drug which is looking promising
We have seen Mineral Resources share price drop over the past month due to decreasing Spodumene Concentrate prices in China. Despite this drop we believe at current prices, this presents a good opportunity.
You are unauthorized to view this page. Username Password Remember Me Forgot Password
We initially recommended a high allocation of this relative value trade, which is no longer appropriate given the recent strength in Tech stocks in the US
CSL has reached the upper end of its trading range. In line with our commitment to optimizing returns and managing risks effectively, we are taking profit on the remaining 2% of our CSL position.
We have seen Mineral Resources share price drop over the past month due to decreasing Spodumene Concentrate prices in China. Despite this drop we believe at current prices, this presents a good opportunity.
Yancoal has delivered their quarterly update overnight. This has seen the price rally to $5.75 (+19%)
Pilbara is one of our favourites and has been a big winner for us over the last 3 years. Despite this the headwinds have become too great in the medium term with lithium prices falling 78% in the last 12 months.
Amid economic uncertainties, healthcare remains resilient, benefiting from consistent needs and innovation. This strategic move offers stability and growth potential in a fluctuating market.
